Vaccine effectiveness of 99.3% seen in fully vaccinated: Mandaviya

Vaccine effectiveness of 99.3% has been seen in individuals fully inoculated against Covid as per the data uploaded on India Covid-19 Tracker till January 2, the Parliament was told on Friday

Topics
Coronavirus Vaccine

IANS  |  New Delhi 

Vaccine effectiveness of 99.3 per cent has been seen in individuals fully inoculated against Covid as per the data uploaded on India Covid-19 Tracker till January 2, the Parliament was told on Friday.

The Indian Council of Medical Research (ICMR) has developed the India Covid-19 Vaccine Tracker, by merging mainly three national databases -- CoWIN, National Covid-19 Testing database and Covid-19 India portal, Health Minister Mansukh Mandaviya told the Lok Sabha in a written reply.

"The latest data analysed and uploaded till January 2, 2022 depicts vaccine effectiveness of 99.3 per cent in fully vaccinated individuals against Covid-19," he said, adding that the tracker is updated periodically and displays the effectiveness of partial and full vaccination against Covid-19.

He said that the Omicron variant is the dominant variant in the country presently. Whole genome sequencing for Omicron variant is done for all RTPCR positive samples from international travellers arriving since November 28, 2021.

Stressing that the Centre is supporting states in their endeavour to manage Covid-19 since the beginning of the pandemic, Mandaviya said that given the emergence of mutated variants with variable impact on transmissibility, virulence and effectiveness of vaccines, the likelihood of resurgence of Covid-19 trajectory in the country is monitored by various expert committees under ICMR, DGHS and other departments.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus Vaccine
First Published: Sat, February 05 2022. 07:58 IST
RECOMMENDED FOR YOU